American Journal of Cardiology
Volume 103, Issue 8 , Pages 1078-1082 , 15 April 2009

Effect of Hemoglobin Level on Long-Term All-Cause Mortality After Percutaneous Coronary Intervention in African-Americans

Received 9 October 2008 ,Revised 21 December 2008 ,Accepted 21 December 2008.

References 

  1. Reinecke H, Trey T, Wellmann J, Heidrich J, Fobker M, Wichter T, et al. Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J. 2003;24:2142–2150
  2. McKechnie RS, Smith D, Montoye C, Kline-Rogers E, O'Donnell MJ, DeFranco AC, et al Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention. Circulation. 2004;110s:271–277
  3. Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, Garcia E, et al Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol. 2004;44:547–553
  4. Perry GS, Byers T, Yip R, Margen S. Iron nutrition does not account for the hemoglobin differences between blacks and whites. J Nutr. 1992;122:1417–1424
  5. Beutler E, West C. Hematologic differences between African-Americans and whites: the roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume. Blood. 2005;106:740–745
  6. Marmur JD, Poludasu S, Agarwal A, Vladutiu P, Feit A, Lapin R, et al. Bolus-only platelet glycoprotein IIb–IIIa inhibition during percutaneous coronary intervention. J Invasive Cardiol. 2006;18:521–526
  7. Marmur JD, Poludasu S, Agarwal A, Manjappa N, Cavusoglu E. High-dose tirofiban administered as bolus-only during percutaneous coronary intervention. J Invasive Cardiol. 2008;20:53–58
  8. Gottlieb SS. Dead is dead—artificial definitions are no substitute. Lancet. 1997;349:662–663
  9. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research: time for a reassessment?. J Am Coll Cardiol. 1999;34:618–620
  10. Curb JD, Ford CE, Pressel S, Palmer M, Babcock C, Hawkins CM. Ascertainment of vital status through the National Death Index and the Social Security Administration. Am J Epidemiol. 1985;121:754–766
  11. Nutritional Anaemias (Report of a WHO Scientific Group. World Health Organization Technical Report Series No. 405). Geneva: World Health Organisation; 1968;9–10.
  12. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  13. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al ACC/AHA guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002;106:1893–1900
  14. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction (Results of the Thrombolysis In Myocardial Infarction (TIMI), phase II trial). Ann Intern Med. 1991;115:256–265
  15. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853–863
  16. Lin D, Wei L, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80:557–572
  17. Cavusoglu E, Chopra V, Gupta A, Clark LT, Eng C, Marmur JD. Usefulness of anemia in men as an independent predictor of two-year cardiovascular outcome in patients presenting with acute coronary syndrome. Am J Cardiol. 2006;98:580–584
  18. Bunn HF. Pathophysiology of the anemias. In:  Isselbacher KJ,  Braunwald E,  Martin JB,  Fauci AS,  Wilson JD,  Kasper DL editor. Harrison's Principles of Internal Medicine. 13th Ed.. New York: McGraw-Hill; 1994;p. 1720–1721
  19. Dillmann E, Johnson DG, Martin J, Mackler B, Finch C. Catecholamine elevation in iron deficiency. Am J Physiol Regul Integr Comp Physiol. 1979;237:R297–R300
  20. Takahashi M, Kurokawa S, Tsuyusaki T, Kikawada . Studies of hyperkinetic circulatory state in chronic anemia. J Cardiol. 1990;20:331–339
  21. Nikolsky E, Mehran R, Aymong ED, Mintz GS, Lansky AJ, Lasic Z, et al Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. Am J Cardiol. 2004;94:1023–1027
  22. Means RT. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells. 1995;13:32–37
  23. Gach O, Legrand V, Biessaux Y, Chapelle JP, Vanbelle S, Pierard LA. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol. 2007;99:31–35
  24. Husemann W, Fobker M, Pohlen M, Bruch C, Hausberg M, Breithardt G, et al. Impact of haemoglobin concentration and chronic kidney disease in patients with coronary heart disease undergoing percutaneous coronary interventions. Nephrol Dial Transplant. 2007;22:2563–2570

PII: S0002-9149(09)00040-X

doi: 10.1016/j.amjcard.2008.12.032

American Journal of Cardiology
Volume 103, Issue 8 , Pages 1078-1082 , 15 April 2009

Article Tools

* Image Usage & Resolution